Stem Cell Therapy for Motor Neuron Disease in India

Motor Neuron Disease (MND) is an umbrella term for a group of progressive neurological conditions in which the nerve cells controlling voluntary muscle movement gradually degenerate. As motor neurons die, the brain loses its ability to signal muscles, leading to weakness that spreads over time and eventually affects speech, swallowing, and breathing.

There is currently no cure for any form of MND. Standard care — medication, physiotherapy, respiratory support, and assistive devices — focuses on managing symptoms and preserving quality of life rather than reversing nerve damage. This has driven sustained research interest in regenerative approaches, including stem cell therapy, which is being studied in India and internationally for its potential to support surviving motor neurons and slow disease progression.

At Viezec, we evaluate each MND patient individually to determine whether an investigational stem cell protocol is medically appropriate, and we are transparent that this remains a research-stage intervention rather than an established cure.

Schedule a Consultation

MND is not a single disease but a family of related conditions, each affecting motor neurons in a somewhat different pattern:

• Amyotrophic Lateral Sclerosis (ALS) — the most common and best-known form, affecting both upper and lower motor neurons. Read our dedicated guide to stem cell therapy for ALS.
• Primary Lateral Sclerosis (PLS) — affects only upper motor neurons, typically progressing more slowly than ALS.
• Progressive Muscular Atrophy (PMA) — affects only lower motor neurons, causing weakness and muscle wasting.
• Progressive Bulbar Palsy (PBP) — primarily affects the muscles used for speech and swallowing.
• Spinal Muscular Atrophy (SMA) — a distinct, usually genetic and childhood-onset condition; see our dedicated SMA page for specifics.

Because these subtypes differ in which neurons are affected, in typical age of onset, and in rate of progression, an accurate diagnosis always comes before any treatment — including regenerative therapy — is discussed.

Traditional MND management includes medications such as riluzole and edaravone, physiotherapy, occupational therapy, speech and swallowing support, and respiratory care. These approaches can slow symptom progression and manage complications, but they do not repair or replace damaged motor neurons. This gap is what has driven interest in cell-based, regenerative approaches as a complementary avenue of research.

Investigational stem cell approaches for MND generally explore a few mechanisms rather than direct neuron replacement, which remains extremely difficult given how specialized motor neurons are:

• Neurotrophic factor secretion — mesenchymal stem cells (MSCs) can release growth factors that may support the survival of remaining motor neurons.
• Anti-inflammatory signaling — MSCs are studied for their ability to calm the chronic neuroinflammation associated with MND progression.
• Reduction of oxidative stress — some preclinical research suggests stem cell-derived factors may lower oxidative damage in the motor neuron environment.
• Supportive cell types under research — mesenchymal stem cells, neural stem cells, and induced pluripotent stem cell (iPSC)-derived progenitors are all active areas of study, each at different stages of clinical evidence.

None of these approaches are currently approved cures for MND anywhere in the world. Published trial results have been mixed — some studies report a slower rate of functional decline in certain patient subgroups, while others have not met their primary endpoints. Patients and families should treat any specific claim of “cure” or guaranteed improvement with caution.

India has become an active center for regenerative medicine research, with institutions and private clinics investigating stem cell-based protocols for various neurological conditions, including MND. The Indian Council of Medical Research (ICMR) and the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) set the regulatory framework governing how these investigational therapies may be offered — generally within regulated clinical research or case-by-case evaluation settings rather than as an approved standard treatment.

At Viezec, our approach for any MND patient begins with confirming the specific subtype and disease stage, since candidacy and expected outcomes can differ meaningfully between, for example, ALS and PMA.

• Review of neurological history, EMG/nerve conduction results, and functional rating scores
• Bloodwork and imaging to confirm eligibility and rule out contraindications
• A clear, evidence-based discussion of realistic expectations — not guarantees
• If appropriate, cell collection (typically bone marrow or adipose-derived), laboratory processing, and administration under medical supervision
• Structured follow-up to track function, safety, and any adverse events

What this is not: a promised cure, a replacement for standard neurological care, or a guaranteed way to reverse existing muscle weakness or paralysis.

Investigational stem cell products for MND are typically administered by one of the following routes, chosen based on the patient’s subtype, disease stage, and treatment goals:

• Intrathecal injection (into the cerebrospinal fluid via lumbar puncture) — the most studied route in motor neuron disease trials, intended to bring cells or their secreted factors closer to spinal motor neurons.
• Intravenous (IV) infusion — a systemic route sometimes used alongside intrathecal dosing for broader anti-inflammatory support.
• Intramuscular injection — used in some earlier-phase protocols targeting specific muscle groups.

All procedures should take place in a GMP-compliant laboratory and clinical setting, administered by clinicians experienced in neurological care, with monitoring for immediate and delayed reactions.

Costs vary depending on the MND subtype, disease stage, number of sessions, and the type of stem cells used (autologous or allogeneic). As a general reference point, complete stem cell therapy programs for motor neuron diseases in the US, UK, and Germany typically range from roughly $18,000 to $45,000, while India offers comparable medical standards — GMP-certified labs, internationally trained neurologists — at a significantly lower cost. A personalized estimate is only possible after your medical reports have been reviewed.

Get a Personalized Cost Estimate

The information on this page is provided for educational purposes and does not constitute medical advice, diagnosis, or a treatment recommendation for any individual. MND affects each patient differently, and general information cannot substitute for an in-person evaluation by a qualified neurologist. Stem cell-based interventions for MND, beyond currently approved uses, are investigational in India and are typically available only within regulated clinical research or case-by-case evaluation frameworks. If symptoms suddenly worsen — particularly breathing difficulty — seek emergency medical care immediately.

Motor Neuron Disease encompasses several related but distinct conditions, and while no cure currently exists for any of them, ongoing research into stem cell therapy offers a genuinely active area of scientific interest. India’s combination of research infrastructure, regulatory oversight, and lower treatment costs has made it a destination many international patients consider when exploring investigational regenerative options. At Viezec, every evaluation starts with confirming the specific MND subtype and stage, followed by an honest, evidence-based discussion of what stem cell therapy can — and cannot — currently offer.

Talk to Our Experts →